We had the pleasure of meeting with Chia-Chun Chiang (Mayo Clinic, Rochester, MN, USA) to discuss a real world study of ubrogepant in participants with acute migraine.
The abstract entitled: ‘Real World Efficacy, Tolerability and Safety of Ubrogepant’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What is the current role of gepants in the treatment armamentarium for migraine? (0:30)
- What have clinical studies taught us about the efficacy and safety of ubrogepant? (1:57)
- Could you tell us a little about your real world study and its findings? (3:33)
- What factors were found to predict a good response to ubrogepant? (5:35)
Disclosures: Chia-Chun Chiang has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Stephanie Nahas, AHS 2021: HALO Long Term Study Results
We had the great pleasure of meeting with Stephanie Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss the HALO long term extension study investigating long term efficacy and tolerability of fremanezumab in patients with episodic and chronic migraine. The abstract ‘Clinically Meaningful Responses to Fremanezumab Treatment in Episodic and Chronic Migraine […]
Stephanie Nahas, AHS 2021: Results from the CaMEO Study
We had the great pleasure of meeting with Stephanie Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss the CaMEO results, a web-based survey to characterize self-reported use of preventive medications for migraine and treatment gaps. The abstract ‘Characterizing preventive treatment gaps in migraine: Results from the CaMEO study’ & ‘Optimal acute […]
Robert Shapiro, AHS 2021: COVID-19 Incidence and Mortality Among Individuals with Migraine
touchNEUROLOGY met with Robert Shapiro (Larner College of Medicine at the University of Vermont, Burlington, VT, USA) to discuss the impact of COVID-19 on individuals with migraine. The abstract ‘Migraine Is Associated With Higher Incidence of COVID-19, and Higher Frequency of COVID-19 Symptoms, but Lower COVID-19-Associated Health Care Resource Utilization Rates’ was presented at the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!